











## Message from the Coordinators

Dear AETIONOMY partners,

After a couple of heavy months of updates to the DoW and the Annual Report for everyone, special thanks to Jacqueline and Stephan, the focus for us all turns to the science (please PO don't remind us that there will be revisions coming to both!)

Back to the science. With frenzied efforts overtaking all of the clinical partner's laboratories there are plenty of sample transfer logistics ongoing, thanks to Stephanie at ICM for keeping a handle on this, and soon there will be a glut of data flowing. With these data will come the inevitable challenges, which we rely on the close partnerships between WPs 2, 3 and 5 to help address.

The opportunities and the challenges of these final few months of the project will be the focus of the face to face WP 5/3 organised workshop hosted in the UK at the end of April. We hope that these discussions will spur us on towards the collaborative endpoint for AETIONOMY as we move into the final phase.

Now to some business and reminders, please all take note of the timelines on the final page of the bulletin and for those partners who will be exchanging data and integrating data into the AKB <u>from May 25th</u> this year, please go back and review Marc Stauch's email from March with your institutions Data Privacy Officers as the GDPR is an important consideration. Last but not least please review the deliverables due to your work package and ensure that we post reports on time.

**Thanks** 

Your PO (Phil, Martin, Jaqueline, Stephan and Tobias)

#### **General Information**

#### **Upcoming Meetings**

- WP 3-5 Workshop & Datathon UCB, UK April 26 & 27 2018
- EAN Conference 16-19 June 2018, Lisbon
- ISMB Conference 6-10 July 2018, Chicago
- PO/SC Meeting, Luxembourg 5/6 July 2018
- Final WP3-5 Workshop & Datathon BBRC, 21 Sept
- Final General Assembly and NDD Symposium on 29<sup>th</sup> & 30<sup>th</sup> Nov 2018 Bonn, Germany

Reminder that all publications need to be submitted to the Project Office <u>before</u> submission. Same for Congress abstracts, etc.!

Please review the Project Agreement for more details. Remember to follow the **IMI mandatory** communication guidelines with regards to funding statements and logos.

Did you know that **AETIONOMY** should always be capital letters?

# Deliverables due to IMI in 2017 (DoW v5.1, Aug 2017)

- D5.3.2 & D5.3.5 due M48
- D2.5.3.4 due M50
- D3.9.3.1 due M50
- D5.1.6.4 due M52
- D1.4.2 due M55

#### WP1 – Governance & Coordination

- The annual report for year 4 was successfully submitted to IMI on time. We have had a first set of comments and expect most of them after 9<sup>th</sup> April.
- The final amendment to the Description of Work, v6.0 of March 2018 was submitted to IMI. Thanks to those that contributed. We will keep you posted on IMI feedback.
- The Final Symposium and last General Assembly date will now be held on the 29<sup>th</sup> & 30<sup>th</sup> November 2018. This will take place in Bonn, Hotel Hilton. We are lining up our speakers and it will be a great meeting. We will communicate further info in the next bulletin. We expect all partners to present at this final conference on neurodegeneration.
- The PO again would like to ask all WPs to please try to submit the deliverables on time as we are being measured on this!

#### WP2 – Knowledge & Data Management

- WP2 continues to work on improving the usability of the AKB. UL is currently working on integrating the <a href="Ada System">Ada System</a> to the AKB, this will bring new analytical pipelines based on Machine Leaning to be described in the D2.4.3.2.
- The new datasets received are being processed or under curation. This includes the UKB AD Inflammation study, KCL and Tuebingen studies, and 14 UCB studies.
- WP2 partners are proceeding on the enrichment of the 3D brain imaging data of the Virtual Dementia Cohort (VDC) to incorporate processed functional and structural information (fRMI and DTI data).

Additionally information of the BEL disease models and Bayesian Networks (BNs) will be analyzed for the incorporation into the 3D brain simulation. A meeting was held to plan this integration of BEL/BN related information via the TVB interface.

## WP3 – Knowledge Integration & Mining

At EMC a new event-based modeling approach (EBM) has been developed in the past months, that seems to be more robust and accurate than other published approaches. A property of the new approach is that it is also calculating the disease stage per subject. In the last weeks this modeling was applied on 1.737 ADNI cohort subjects. ADrelated non-imaging and imaging biomarkers, including volume measures of hippocampus subparts, were used as events. APOE-epsilon4-related info was used to see the effect on the EBM outcome.

The first finding seems to be that the event order is not influenced by APOE, but that events are becoming abnormal more early (disease staging) in the case of APOE != 0.

EBM will applied to other cohort data and further experiments will be done, also using other (different) AD-related genetic info as well as relevant Chromosome 17 SNPs.

- Partners UCB and Fraunhofer are developing and verifying the Bayesian Network approach for patient stratification.
- Another activity of this collaboration is the validation of the ADNI-based AD risk model applied to the AddNeuroMed cohort data.
- Finally, this team is generating a virtual AD patient cohort with a similar feature distribution like in the ADNI cohort.

During the VDC workshop in February the integration of the different approaches for the generation of the VDC ADNI Avatar were discussed and reported in deliverable D2.5.3.3. For more information check the BSCW AETIONOMY workspace under the URL: https://bscw-biosc.scai.fraunhofer.de/bscw/bscw.cgi/45405

• A webinar 'Mining on Bayesian representations of major cohort studies (incl. ADNI and PPMI)' is planned in April to present the result of these different Bayesian Network approaches.

### WP4 – Ethical & Legal Governance

LUH has circulated the finalised data protection supplemental agreement for signing to all partners that will continue to handle patient data in the project after 25 May 2018, when the new EU General Data Protection Regulation (GDPR) takes effect; the cooperation of partners in getting this document signed is much appreciated, as it is designed to ensure that data processing in the project remains compatible with the updated EU data protection regime. Dr Marc Stauch, LUH, has also addressed the GA of AETIONOMY's sisterproject, PRECISESADS, in Ascot, UK on compliance issues facing that project too that is a result of the GDPR."

## WP5 – Clinical Validation (1/2)

Sarah Bujac, Luc Canard and Ullrich Wuellner have been exploring the PD EFPIA data in the SAS Multi-sponsor Environment. The aim is to demonstrate the utility of the EFPIA data and, in the process, gain insights into the effect of baseline characteristics, such as age and gender, on dopamine agonist response in Early PD.

#### AETIONOMY sample plan:

90% of the shipping plan will be completed by the end of the month /  $1^{st}$  week of April. The remaining 10% are part of external cohorts' samples that we are currently selecting and preparing for shipment to the different analysis labs. These shipments are summarized below, with an actual update on their status:

| From                          | Samples                   | То               | Status    | Actual/Estimated date |  |  |
|-------------------------------|---------------------------|------------------|-----------|-----------------------|--|--|
|                               | 105 DNA                   | ICM              | Partially | 26 MARCH 18           |  |  |
| KI (Prof. Svenningsson)       | 150 DNA add. Cohort       | ICM              | Planned   | Extraction ongoing    |  |  |
|                               | 32 CSF                    | UKB (MH)         | Planned   | 3 APR 18              |  |  |
|                               | 32 CSF                    | IDIBAPS          | Planned   | 3 APR 18              |  |  |
|                               |                           |                  |           |                       |  |  |
|                               | 94 DNA                    | ICM              | OK        | 26 FEB 18             |  |  |
|                               | 48 DNA                    | ICM              | Planned   | 28 MARCH 18           |  |  |
| UKB (Prof. Wuellner)          | 22 CSF                    | KI               | OK        | 28 MARCH 18           |  |  |
|                               | 22 CSF                    | IDIBAPS          | OK        | 5 MARCH 18            |  |  |
|                               | 22 CSF                    | UKB (MH)         | NA        | Internal transfer     |  |  |
|                               |                           |                  |           |                       |  |  |
|                               | 240 DNA add. Cohort       | ICM              | Planned   | Selection ongoing     |  |  |
| UKB (Prof. Heneka)            | 220 CSF add. Cohort       | KI               | OK        | 20 FEB 18             |  |  |
| Notice of the second          | 220 CSF add. Cohort       | IDIBAPS          | OK        | 26 FEB 18             |  |  |
|                               |                           |                  |           |                       |  |  |
|                               | 47 CSF + 14 add. Cohort   | KI               | OK        | 7 MARCH 18            |  |  |
| ICM (Prof. Corvol)            | 37 CSF + 9 add. Cohort    | UKB (MH)         | OK        | 7 MARCH 18            |  |  |
| icivi (Pioi. Colvoi)          | 47 CSF + 14 add. Cohort   | IDIBAPS OK       |           | 7 MARCH 18            |  |  |
|                               | 318 DNA + 642 add. Cohort | UKB (UW) Planned |           | 3 APR 18              |  |  |
|                               |                           |                  |           |                       |  |  |
|                               | 7 DNA + 364 add. Cohort   | ICM              | NA        | Internal transfer     |  |  |
| IM2A (Prof. Dubois)           | 23 CSF add. Cohort        | KI               | Planned   | 3 APR 18              |  |  |
|                               | 23 CSF add. Cohort        | UKB (MH)         | Planned   | 3 APR 18              |  |  |
|                               | L                         |                  |           |                       |  |  |
| IDIBAPS (Prof. Sanchez-Valle) | 137 CSF add. Cohort       | UKB (MH)         | OK        | 6 MARCH 18            |  |  |
| ,                             | 137 CSF add. Cohort       | KI (PS)          | Planned   | 3 APR 18              |  |  |

## WP5 – Clinical Validation (2/2)

- AETIONOMY sample analysis update:
   ~350 DNA samples have already been genotyped at ICM, i.e. 35% of the total DNA samples to be analyzed.
- AETIONOMY data management plan:
  - Clinical study data entry into REDCap eCRF is finished at all sites.
  - Queries have been issued, with a rate of 80% being resolved to date.
  - Database lock is planned early April after the listings review meeting. New queries may be issued after that.
- AETIONOMY data validation plan:

We are setting up a Data Review Committee to be held beginning of April to validate the AETIONOMY clinical study dataset.

This dataset that will then be analyzed, by the end of April.

#### **Publications Corner**

Mouton-Liger F et al. (ICM):
 Parkin deficiency amplifies NLRP3
 inflammasome activation by attenuating an A20-dependent negative feedback loop.
 GLIA in press.

#### Happy Easter to all



# Important Timelines to Project End

| +  |                               |  |   |                      |     |   |  |        |  |  |                                       |              |                            |
|--|-------------------------------|--|---|----------------------|-----|---|--|--------|--|--|---------------------------------------|--------------|----------------------------|
|  |                               |  |   |                      |     |   |  |        |  |  |                                       |              |                            |
| M49  | M50                           | M51  | M52                                       | M52                  | M53 | M54   | M55  | M56    | M57  | M58  | M59                                   | M60          |                            |
| 31-Jan-18  | 15-Feb-18                     | Mar-18   | 26 or 27 Apr                              | 30-Apr-18            | may | june  | Jul-18                                       | August | 20-21 Sep  | 3-5 Oct 18   | 29 & 30 Nov                           | 31-Dec       | 28-Feb-19                  |
| all known<br>samples<br>documented in<br>excel planner | I.                            |  | final Workshop<br>WP3/5 &<br>datathon? UK | results<br>available |     | biomarker<br>data analysis                        | SC mtg /<br>results<br>interpretation<br>UL  |        | final Workshop<br>WP3/5 &<br>datathon?<br>BBRC,<br>Barcelona | Granada<br>Genomics<br>Conference /<br>Joint<br>Taxonomy<br>Mtg? | NDD<br>Conference &<br>Final GA       | Project ends | Final report<br>due to IMI |
|  | io need ready                 |  |   |                      |     |   |  |        |  |  |                                       |              |                            |
|  | Project Plan for analysis due | Newsletter<br>Identification of<br>new mechanisms<br>for NDD |   |                      |     | Newsletter -<br>the Virtual<br>Dementia<br>Cohort | 02-05/2018<br>5th July<br>Luxembourg<br>(JC) |        |  |  | Newsletter -<br>The new<br>Taxonomies |              |                            |

Did you know that all the project deliverables submitted to IMI are available on our BSCW Server?

Check them out at: <a href="https://bscw-biosc.scai.fraunhofer.de/bscw/bscw.cgi/42644">https://bscw-biosc.scai.fraunhofer.de/bscw/bscw.cgi/42644</a>